

Liza M. Walsh
Selina M. Ellis
WALSH PIZZI O'REILLY FALANGA LLP
Three Gateway Center
100 Mulberry Street, 15th Floor
Newark, New Jersey 07102
Tel: (973) 757-1100

*Attorneys for Plaintiffs Teva Branded Pharmaceutical Products
R&D, Inc., Norton (Waterford) Ltd., and Teva Pharmaceuticals USA, Inc.*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

TEVA BRANDED
PHARMACEUTICAL PRODUCTS
R&D, INC., NORTON (WATERFORD)
LTD., and TEVA
PHARMACEUTICALS USA, INC.

Plaintiffs,

v.

AMNEAL PHARMACEUTICALS OF
NEW YORK, LLC, AMNEAL
IRELAND LIMITED, AMNEAL
PHARMACEUTICALS LLC, and
AMNEAL PHARMACEUTICALS INC.

Defendants.

Civil Action No. 23-cv-20964-SRC-
MAH

**DECLARATION OF LIZA
M. WALSH**

Electronically Filed

I, Liza M. Walsh, hereby declare as follows:

1. I am an attorney admitted to practice before this Court and a partner with the law firm Walsh Pizzi O'Reilly Falanga LLP, counsel for Plaintiffs Teva

Branded Pharmaceutical Products R&D, Inc., Norton (Waterford) Ltd., and Teva Pharmaceuticals USA, Inc. (collectively, “Teva”). I am fully familiar with the facts set forth herein.

2. I submit this Declaration in support of Teva’s Motion to Dismiss Counts 1–10 of Defendants’ Counterclaims (ECF No. 12).

3. Attached as **Exhibit 1** is a true and correct copy of Amneal Pharmaceuticals of New York, LLC’s Notice of Paragraph IV Certification of U.S. Patent Nos. 8,132,712, 9,463,289, 9,808,587, 10,022,509, 10,022,510, 10,086,156, 10,561,808, 10,695,512 and 11,395,889, Concerning ANDA No. 211600 for Albuterol Sulfate Inhalation Aerosol, 90 mcg Per Actuation, and Detailed Factual and Legal Basis of Non-Infringement, Unenforceability, and/or Invalidity, dated August 24, 2023.

4. Attached as **Exhibit 2** is a true and correct copy of Chapter 5 “Inhalation and Nasal Drug Products—General Information and Product Quality Tests,” *United States Pharmacopeia-National Formulary* (Official Date: Aug. 1, 2023).

5. Attached as **Exhibit 3** is a true and correct copy of excerpts from *Approved Drug Products with Therapeutic Equivalence Evaluations*, Food and Drug Administration (44th ed. 2024).

I declare that the foregoing statements made by me are true.

Dated: January 26, 2024

Respectfully submitted,

/s/ Liza M. Walsh

Liza M. Walsh (lwalsh@walsh.law)
WALSH PIZZI O'REILLY FALANGA
LLP

Three Gateway Center
100 Mulberry Street, 15th Floor
Newark, New Jersey 07102
Tel: (973) 757-1100

*Attorney for Plaintiffs Teva Branded
Pharmaceutical Products R&D, Inc.,
Norton (Waterford) Ltd., and Teva
Pharmaceuticals USA, Inc.*